Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

522 trials

NCT04428554
Recruiting
Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy
Phase 2 · France · 20 sites
Registry update: 18 Nov 2025
NCT04389632
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 · Switzerland, Spain, France, United Kingdom, South Korea, Taiwan, United States · 137 sites
Registry update: 6 Jul 2026
NCT03973671
Recruiting
Prospective Sample Collection for Cancer of Bladder
Not applicable · Belgium · 1 site
Registry update: 28 Mar 2024
NCT05204108
Recruiting
Preoperative Detection of Muscle Invasion in Bladder Cancer with Contrast-enhanced Ultrasonography
Not applicable · China · 1 site
Registry update: 13 Jan 2025
NCT04510129
Recruiting
A Multicenter Cancer Biospecimen Collection Study
Not applicable · United States · 1 site
Registry update: 12 Mar 2025
NCT04934540
Recruiting
The Global En Bloc Resection of Bladder Tumour Registry
Not applicable · Hong Kong · 2 sites
Registry update: 27 Oct 2026
NCT04198766
Recruiting
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Phase 1/2 · South Korea, Singapore, Taiwan, United States · 60 sites
Registry update: 6 Nov 2026
NCT04197414
Recruiting
Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
Not applicable · South Korea · 1 site
Registry update: 13 Dec 2019
NCT04410302
Recruiting
Patient-Derived Xenografts to Reduce Cancer Health Disparities
Not applicable · United States · 2 sites
Registry update: 20 Aug 2026
NCT07673016
Recruiting
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
Not applicable · Puerto Rico, United States · 23 sites
Registry update: 29 Jun 2026
NCT07614594
Recruiting
Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis
Not applicable · China · 1 site
Registry update: 2 Jul 2026
NCT04623502
Recruiting
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
Not applicable · United States · 1 site
Registry update: 28 Jan 2026
2023-509821-29-00
Recruiting
Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial: ARCADIA study
Phase 2 · Italy · 1 site
Registry update: 3 Aug 2026
NCT04104776
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Phase 1/2 · Spain, France, United Kingdom, Italy, South Korea, Poland, United States · 76 sites
Registry update: 19 Aug 2026
NCT03379909
Recruiting
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer
Phase 2 · Netherlands · 3 sites
Registry update: 21 Sept 2023
NCT03945162
Recruiting
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Phase 2 · Canada, United States · 16 sites
Registry update: 24 Nov 2025
NCT03866382
Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Phase 2 · Puerto Rico, United States · 582 sites
Registry update: 4 Nov 2026
NCT04075305
Recruiting
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Not applicable · Australia, Belgium, Canada, Germany, Denmark, United Kingdom, Italy, Netherlands, United States · 18 sites
Registry update: 5 Mar 2026
NCT03664869
Recruiting
Intravesical instillation therapy with bacillus Calmette-Guérin (BCG) and sequential BCG and electromotive mitomycin-C (EMDA-MMC) in patients with high-risk non-muscle-invasive bladder carcinoma (FINNBLADDER 10)
Phase 3 · Finland · 1 site
Registry update: 19 Sept 2024
NCT03787056
Recruiting
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
Not applicable · France · 17 sites
Registry update: 16 Jul 2021

Ordered by registry start date. Freshness and sponsorship never change the order.